Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1713
    +0.0019 (+0.16%)
     
  • GBP/USD

    1.2621
    -0.0001 (-0.01%)
     
  • Bitcoin GBP

    55,713.02
    +379.53 (+0.69%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,343.72
    +175.65 (+0.44%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

CureVac says in talks with potential vaccine development partners

FILE PHOTO: Employee Philipp Hoffmann, of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus (COVID-19) disease at a laboratory in Tuebingen

FRANKFURT (Reuters) - CureVac <5CV.DE> is still in discussions with pharma majors to find a potential partner for its experimental COVID-19 vaccine, the German biotech firm's chief executive said on Thursday.

"The location of the partner does not play a role. We are looking for a partner who is best placed to support us," Chief Executive Franz-Werner Haas told a media briefing.

He said that a global infrastructure to monitor possible side effects after market launch was among the aspects to be addressed by a partner, but he added that CureVac may also outsource this task to a service provider.

Haas said the group was close to launching a Phase III trial with about 36,000 participants to find out whether its vaccine can prevent infections and that it plans to produce 300-400 million vaccine doses next year.

(Reporting by Ludwig Burger and Caroline Copley; Editing by Riham Alkousaa)